#AAD26: Biogen declares Phase 2 lupus success for anti-BDCA2 antibodynews2026-03-28T21:24:57+00:00March 28th, 2026|Endpoints News|
FDA approves Rocket’s gene therapy for ultra-rare immune diseasenews2026-03-27T15:13:30+00:00March 27th, 2026|Endpoints News|
AstraZeneca’s in vivo CAR-T led to early responses, but one death in China trialnews2026-03-27T12:00:35+00:00March 27th, 2026|Endpoints News|
After tumultuous year, Sarepta plots rebound with early data on RNA therapiesnews2026-03-25T15:41:06+00:00March 25th, 2026|Endpoints News|
Ocugen heads to Phase 3 with gene therapy for geographic atrophynews2026-03-24T15:40:16+00:00March 24th, 2026|Endpoints News|
Q&A: Controversial embryo editing entrepreneur Cathy Tie on her new startupnews2026-03-24T14:10:54+00:00March 24th, 2026|Endpoints News|
Aspen’s personalized Parkinson’s therapy shows early promisenews2026-03-18T13:00:44+00:00March 18th, 2026|Endpoints News|
China mRNA therapy startup Innorna to test gout treatment in USnews2026-03-17T11:00:08+00:00March 17th, 2026|Endpoints News|
China startup CirCode gets clearance for trial of circular RNA therapynews2026-03-16T12:30:43+00:00March 16th, 2026|Endpoints News|
Ultragenyx’s gene therapy hits key endpoint in Phase 3 trial for blood ammonia diseasenews2026-03-13T14:18:51+00:00March 13th, 2026|Endpoints News|
